Korean J Obstet Gynecol Search


Korean Journal of Obstetrics & Gynecology 2006;49(8):1655-1659.
Published online August 1, 2006.
Differences of EDR Chemoresistance Assay and Prognosis between Recurrent Micropapillary Serous Ovarian Carcinoma and Serous Ovarian Carcinoma.
Moon Seok Cha
Department of Gynecology and Obstetrics, College of Medicine, Dong-A University, Busan, Korea. mscha@dau.ac.kr
The purpose of this study was to identify chemoresistance and prognosis differences between recurrent micropapillary serous ovarian carcinoma (MPSC) and serous ovarian carcinoma. METHODS: The Extreme drug resistance (EDR) assay was performed in 13 recurrent micropapillary serous ovarian carcinoma and 56 recurrent serous ovarian carcinoma. RESULTS: Mean age of MPSC and Serous ovarian cancer were 41.1 and 58.0 respectively (p<0.05). Etoposide and Doxil were the two least resistance chemotherapeutic agents to recurrent MPSC but the most resistance agents to recurrent serous ovarian cancer. Taxol and cisplatin were the two most resistance agents to MPSC. The mean follow up was 42 months (range 1-173) The five-year overall survival rate of MPSC and serous ovarian carcinoma were 71.6% and 33.9% respectively. The mean survival were 136 months in MPSC compared with 72 months in serous ovarian carcinoma (p<0.035). CONCLUSION: In this retrospective analysis, MPSC showed very different in EDR results and favorable prognosis compare to serous ovarian carcinoma.
Key Words: Micropapillary serous ovarian cancer (MPSC), Serous ovarian carcinoma, Extreme drug resistance assay (EDR), Prognosis
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 54 View
  • 0 Download
Related articles in Obstet Gynecol Sci

Article category

Browse all articles >


Browse all articles >

Editorial Office
4th Floor, 36 Gangnam-daero 132-gil, Gangnam-gu, Seoul 06044, Korea
Tel: +82-2-3445-2382    Fax: +82-2-3445-2440    E-mail: journal@ogscience.org                

Copyright © 2020 by Korean Society of Obstetrics and Gynecology. All rights reserved.

Developed in M2community

Close layer
prev next